

**Entry Clone Source:** MGC

**Entry Clone Accession:** IMAGE:5122305

**SGC Construct ID:** LTB4DHA-c007

**GenBank GI number:** gi|28570172

**Vector:** pNIC28-Bsa4. Details [[PDF](#)] ; Sequence [[FASTA](#)] or [[GenBank](#)]

**Amplified construct sequence:**

CATATGCACCACATCATCATCATCATCATTC  
TTCTGGTAGATCTGGGTACCGAGA  
ACCTGTACTTCAATCCATGACTAAG  
ACATGGACCCCTGAAGAACGACTTTGT  
TGGCTATCCTACTAATAGTGACTTTG  
AGTTGAAGACATCTGAGCTCCCACCC  
TTAAAAAAATGGAGAGGGCCTGCTTGA  
AGCTTGTTCCTCACCGTGATCCCT  
ACATGAGAGTGGCAGCCAAAAGATTG  
AAGGAAGGGTGTACAATGATGGGCA  
GCAAGTGGCCAAAGTTGTGGAAAGTA  
AAAATGTAGCCCTACCAAAAGGAAC  
ATTGTACTGGCTTCTCCAGGCTGGAC  
AACGCACCTCCATTCTGATGGGAAAG  
ATCTGGAAAAGCTGCTGACAGAGTG  
CCAGACACAATACCAACTGTCTTGGC  
TCTGGGGACAGTTGGCATGCCAGGCC  
TGACTGCCTACTTGGCTACTTGAA  
ATCTGTGGTGTGAAGGGTGGAGAAC  
AGTGATGGTTAATGCAGCAGCTGGAG  
CTGTGGGCTCAGTCGTGGCAGATT  
GCAAAGCTCAAGGGCTGCAAAGTTGT  
TGGAGCAGTAGGGTCTGATGAAAAGG  
TTGCCTACCTTCAAAAGCTTGGATT  
GATGTCGTTAACTACAAGACGGT  
AGAGTCTTGGAAAGAACCTTGAAGA  
AAGCGTCTCCTGATGGTTATGATTGT  
TATTTGATAATGTAGGTGGAGAGTT  
TTCAAACACTGTTATCGGCCAGATGA  
AGAAATTGGAAGGATTGCCATATGT  
GGAGCCATCTACATATAACAGAAC  
CGGCCACTTCCCCCAGGCCACCC  
CAGAGATTGTTATCTATCAGGAGCT  
CGCATGGAAGCTTTGTCGTCACCG  
CTGGCAAGGAGATGCCGCAAAAG  
CTCTGAAGGACTTGCTGAAATGGGTC  
TTAGAGGGTAAATCCAGTACAAGGA  
ATATATCATTGAAGGATTGAAAACA  
TGCCAGCCGCATTATGGGAATGCTG  
AAAGGAGATAATTGGGAAGACAAT  
AGTGAAGCATAACAGTAAAGGTGGA  
TACGGATCCGAA

**Final protein sequence (Tag sequence in lowercase):**

mhhhhhhsgvdlgtenlyfq^smTK  
TWTLKKHFVGYPTNSDFELKTSELPP  
LKNGEVLLEALFLTVDPYMRVAAKRL  
KEGDTMMGQQVAKVVESKNVALPKGT  
IVLASPGWTTHSISDGKDLEKLLTEW  
PDTIPLSIALGTVGMPGLTAYFGLLE  
ICGVKGGETVMVNAAGAVGSVVGQI  
AKLKGCKVVGAVGSDEKVAYLQKLGF  
DVVFNYKTVESLEETLKKASPDYDCY  
FDNVGGEFSNTVIGQMKKFGRIAICG  
AISTYNRTGPLPPGPPPEIVIYQELR  
MEAFVVYRWQGDARQKALKDLLKWVL  
EGKIQYKEYIIEGFENMPAAFMGMLK  
GDNLGKTIVKA

^ TEV cleavage site

**Tags and additions:** TEV Cleavable N-terminal His6 tag.

**Host:** BL21 (DE3)R3-pRARE2 (Phage resistant strain).

**Growth medium, induction protocol:** 10µl of a glycerol stock was inoculated into 3ml of TB medium (supplemented with 50µg/µl kanamycin) in a 15ml culture tube and cultured at 37°C o/n in a shaking incubator (275rpm). Next day 1ml of o/n culture was used to inoculate 1 litre of TB medium and grown at 37°C with vigorous shaking (180rpm) until the culture reaches an OD<sub>600</sub> of 1.5. Temperature was reduced to 18°C, and cells were induced with IPTG at concentration of 0.5 mM and cultivated for 16 hours. Cells were harvested, centrifuged at 6500rpm for 10 minutes, and the pellet was stored at -20°C until further use.

**Binding buffer:** 50 mM HEPES pH 7.5; 500 mM NaCl; 5 mM Imidazole, 5% Glycerol.

**Extraction buffer, extraction method:** Thawed cell pellets were dissolved in 30-40ml of binding buffer. Cells were lysed by sonication (3x2 minutes) in a 50ml conical tube. After lysis the cell lysate was centrifuged at 4°C for 45 minutes at 21,000rpm.

**Column 1:** Ni-sepharose resin.

**Column 1 Buffer:**

**Wash Buffer:** 50 mM Tris-HCl pH 7.5; 500 mM NaCl; 5% glycerol; 30 mM Imidazole.

**Elution Buffer:** 50 mM HEPES, pH 7.5; 500 mM NaCl; 5% glycerol; 250 mM Imidazole.

**Column 1 Procedure:** The clear supernatant after centrifugation was passed through a Ni-sepharose (2.5ml resin) column twice. The column was washed with 50ml of wash buffer, and protein was eluted with 15ml of elution buffer.

**Column 2:** HiLoad 16/60 Superdex 200 prep grade 120ml, GE Healthcare.

**Column 2 Buffers:** 10 mM HEPES, pH 7.5; 500 mM NaCl; 5% glycerol; 0.5 mM TCEP.

**Column 2 Procedure:** The eluted fractions from the Ni-affinity HisTrap columns were loaded on the gel filtration column in GF buffer at 1.0ml/min. Eluted proteins were collected in 1ml fractions.

**Protein concentration:** 11.2mg/ml using Vivaspin 10K concentrators

**Mass spectrometry characterization:** The protein had an experimental mass of 38183 Da corresponds to theoretical mass, 38183.2 Da, as determined by ESI-TOF MS.

**Crystallisation:** Crystals were grown by vapour diffusion in sitting drops at 4°C. Before crystallisation setup protein was incubated with 5 mM of NADP and 2.0 mM of Raloxifene. A sitting drop consisting of 50µl protein and 100µl well solution was equilibrated against well solution containing 10% PEG 10K, 8% EtGly, 0.1 M HEPES pH 7.5. Crystals were mounted in the presence of 25% ethylene glycol and flash-cooled in liquid nitrogen.

**Data Collection:**

**Resolution:** 2.3 Å

**X-ray source:** SLS-X10, single wavelength.